Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Current Leases (2020 - 2024)

Historic Current Leases for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Q4 2024 value amounting to $1.7 million.

  • Mirum Pharmaceuticals' Current Leases rose 5480.07% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.7 million, marking a year-over-year increase of 5480.07%. This contributed to the annual value of $1.7 million for FY2024, which is 5480.07% up from last year.
  • Per Mirum Pharmaceuticals' latest filing, its Current Leases stood at $1.7 million for Q4 2024, which was up 5480.07% from $1.5 million recorded in Q3 2024.
  • In the past 5 years, Mirum Pharmaceuticals' Current Leases ranged from a high of $1.7 million in Q4 2024 and a low of $358000.0 during Q1 2024
  • Over the past 5 years, Mirum Pharmaceuticals' median Current Leases value was $741500.0 (recorded in 2022), while the average stood at $850800.0.
  • Over the last 5 years, Mirum Pharmaceuticals' Current Leases had its largest YoY gain of 5480.07% in 2024, and its largest YoY loss of 6083.15% in 2024.
  • Over the past 5 years, Mirum Pharmaceuticals' Current Leases (Quarter) stood at $636000.0 in 2020, then rose by 11.79% to $711000.0 in 2021, then skyrocketed by 30.94% to $931000.0 in 2022, then rose by 18.58% to $1.1 million in 2023, then skyrocketed by 54.8% to $1.7 million in 2024.
  • Its last three reported values are $1.7 million in Q4 2024, $1.5 million for Q3 2024, and $1.1 million during Q2 2024.